GAD1 and schizophrenia: This is evident from a number of studies characterizing GABAergic cells using antibodies which target GABA-synthesizing enzymes glutamate decarboxylase 65 and 67 (GAD65 and GAD67) in brain tissues from schizophrenia patients.